2023 |
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma |
|
2023 |
Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia |
|
2023 |
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma |
|
2023 |
Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data |
|
2022 |
LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms |
|
2022 |
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance |
|
2022 |
PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma |
|
2022 |
Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma |
|
2022 |
Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma |
|
2021 |
Targeting the Methyltransferase SETD8 Impairs Tumor Cell Survival and Overcomes Drug Resistance Independently of p53 Status in Multiple Myeloma |
|
2021 |
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma |
|
2021 |
RNA-sequencing Data-Driven Dissection of Human plasma cell Differentiation reveals new potential Transcription Regulators |
|
2021 |
Multi-omics Tumor Profiling Technologies to develop Precision Medicine in Multiple Myeloma |
|
2021 |
The Origin of Preplasmablastic Cells |
|
2020 |
Role of Polycomb Complexes in Normal and Malignant Plasma Cells |
|
2020 |
DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets |
|
2020 |
Kinome expression profiling to target new therapeutic avenues in multiple myeloma |
|
2019 |
CD38 antibodies in multiple myeloma |
|
2019 |
EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation |
|
2019 |
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells |
|
2019 |
Phenotype Characterization of Diffuse Large B cell Lymphoma Cells and Prognostic Impact |
|
2019 |
Treatment may be harmful : mechanisms/preduction/prevention of drug-induced DNA damage and repair in multiple myeloma |
|
2019 |
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance |
|
2018 |
BrdU incorporation in multiparameter flow cytometry : A new cell cycle assessment approach in multiple myeloma |
|
2018 |
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs |
|
2018 |
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells |
|
2017 |
Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Abstract] |
|
2017 |
Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Poster] |
|
2017 |
CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma |
|
2017 |
An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients
who may benefit from epigenetic therapy |
|
2017 |
Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry |
|
2017 |
Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell |
|
2017 |
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma |
|
2017 |
Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry |
|
2017 |
Hypoxia favors the generation of human plasma cells |
|
2016 |
EZH2 in normal hematopoiesis and hematological malignancies |
|
2016 |
Differential effects of lenalidomide during plasma cell differentiation |
|
2016 |
Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy |
|
2016 |
Chetomin, targeting HIF-1a/p300 complex, exhibits antitumour activity in multiple myeloma |
|
2015 |
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma |
|
2015 |
GenomicScape : AnEasy-to-Use Web Tool for Gene Expression Data Analysis. Application
to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells |
|
2014 |
Drug metabolism and clearance system in tumor cells of patients with Multiple Myeloma |
|
2014 |
DNA repair in diffuse large B-cell lymphoma: a molecular portrait |
|
2013 |
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma |
|
2013 |
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors |
|
2012 |
Gene expression-based risk score in diffuse large B-cell lymphoma |
|
2012 |
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients |
|
2012 |
Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation |
|
2011 |
Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation |
|
2011 |
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines |
|
2009 |
An in vitro model of differentiation of memory B cells into plasma blasts and plasma cells including detailed phenotypic and molecular characterization |
|